CLINICAL RESEARCH e-ISSN 1643-3750 © Med Sci Monit, 2015; 21: 987-991 DOI: 10.12659/MSM.892611
Serum Nesfatin-1 is Reduced in Type 2 Diabetes Mellitus Patients with Peripheral Arterial Disease
Received: 2014.09.29 Accepted: 2014.10.27 Published: 2015.04.04
Authors’ Contribution: Study Design A Data Collection B Analysis C Statistical Data Interpretation D Manuscript Preparation E Literature Search F Collection G Funds
DF 1 BC 2 AG 3 DF 1 CF 1 CE 1 EF 1
EF 1
DF 1
Corresponding Author: Source of support:
Background:
Material/Methods: Results:
Conclusions:
MeSH Keywords:
Full-text PDF:
Shimei Ding Wei Qu Shuangsuo Dang Xuan Xie Jing Xu Yuhuan Wang Aiyu Jing Chunhong Zhang Junhong Wang
1 Department of Endocrinology, Second Affiliated Hospital of Medical School of Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China 2 Department of Nuclear Medicine, Second Affiliated Hospital of Medical School of Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China 3 Department of Infectious Diseases, Second Affiliated Hospital of Medical School of Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China
Shuangsuo Dang, e-mail: [email protected] Departmental sources
Nesfatin-1, recently identified as a satiety regulator, elicits an anti-atherosclerosis effect. Our study was designed to determine whether there is an association between serum nesfatin-1 and the development and severity of peripheral arterial disease (PAD) in patients with type 2 diabetes mellitus (T2DM). This cross-sectional study included 355 T2DM patients (200 without PAD and 155 with PAD). T2DM patients with PAD exhibited marked lower serum nesfatin-1 concentrations than those without PAD. Multivariable logistic regression analysis indicated an inverse association of serum nesfatin-1 concentrations with the development of PAD in T2DM patients (OR 0.008, 95% CI 0.002 to 0.028; P
Serum Nesfatin-1 is Reduced in Type 2 Diabetes Mellitus Patients with Peripheral Arterial Disease
Received: 2014.09.29 Accepted: 2014.10.27 Published: 2015.04.04
Authors’ Contribution: Study Design A Data Collection B Analysis C Statistical Data Interpretation D Manuscript Preparation E Literature Search F Collection G Funds
DF 1 BC 2 AG 3 DF 1 CF 1 CE 1 EF 1
EF 1
DF 1
Corresponding Author: Source of support:
Background:
Material/Methods: Results:
Conclusions:
MeSH Keywords:
Full-text PDF:
Shimei Ding Wei Qu Shuangsuo Dang Xuan Xie Jing Xu Yuhuan Wang Aiyu Jing Chunhong Zhang Junhong Wang
1 Department of Endocrinology, Second Affiliated Hospital of Medical School of Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China 2 Department of Nuclear Medicine, Second Affiliated Hospital of Medical School of Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China 3 Department of Infectious Diseases, Second Affiliated Hospital of Medical School of Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China
Shuangsuo Dang, e-mail: [email protected] Departmental sources
Nesfatin-1, recently identified as a satiety regulator, elicits an anti-atherosclerosis effect. Our study was designed to determine whether there is an association between serum nesfatin-1 and the development and severity of peripheral arterial disease (PAD) in patients with type 2 diabetes mellitus (T2DM). This cross-sectional study included 355 T2DM patients (200 without PAD and 155 with PAD). T2DM patients with PAD exhibited marked lower serum nesfatin-1 concentrations than those without PAD. Multivariable logistic regression analysis indicated an inverse association of serum nesfatin-1 concentrations with the development of PAD in T2DM patients (OR 0.008, 95% CI 0.002 to 0.028; P
